Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells

BACKGROUND: Topotecan (TPT) is a therapeutic option for women with platinum-resistant or -refractory ovarian cancer. However, the dose-limiting toxicity of TPT is myelosuppression. This led us to seek a combination treatment to augment TPT anti-cancer activity in a cancer-targeted manner. Ovarian se...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Marianne K, James, Jana, Annunziata, Christina M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379550/
https://www.ncbi.nlm.nih.gov/pubmed/25884494
http://dx.doi.org/10.1186/s12885-015-1231-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379550/
https://www.ncbi.nlm.nih.gov/pubmed/25884494
http://dx.doi.org/10.1186/s12885-015-1231-z

Ejemplares similares